Risk-reducing surgery. Collective, indications and timing

被引：0

作者：

Rhiem, K. M. ^{[1
]}

Pfeifer, K. ^{[2
]}

机构：

[1] Univ Klinikum Koln, Zentrum Familiarer Brust & Eierstockkrebs, Kerpener Str 34, D-50931 Cologne, Germany

[2] TUM, Klinikum Rechts Isar, Lehrstuhl Gynakol & Geburtshilfe, Munich, Germany

来源：

GYNAKOLOGE | 2014年 / 47卷 / 10期

关键词：

Ovarian cancer; Breast cancer; High risk genes; Prophylactic bilateral salpingo-oophorectomy; Prophylactic mastectomy;

D O I：

10.1007/s00129-014-3347-7

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Background. Women carrying a deleterious mutation in the high risk genes BRCA1 or BRCA2 face an increased lifetime risk for breast and ovarian cancer. Prophylactic bilateral mastectomy and salpingo-oophorectomy significantly reduce these risks and improve overall survival. Results and discussion. A decision for or against risk-reducing surgery should be based on an individual risk calculation, a comprehensible communication of these risks and should be implemented in a risk-adapted concept of preventive measures. Mutation carriers with and without cancer are accompanied in the decision-making process by doctors of the specialized centers of the German Consortium for Hereditary Breast and Ovarian Cancer by non-directive counselling.

引用

页码：741 / 745

页数：5

共 9 条

[1] Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study [J].

Bosse, Kristin ;

Rhiem, Kerstin ;

Wappenschmidt, Barbara ;

Hellmich, Martin ;

Madeja, Martin ;

Ortmann, Monika ;

Mallmann, Peter ;

Schmutzler, Rita .

GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1077-1082

[2] Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality [J].

Domchek, Susan M. ;

Friebel, Tara M. ;

Singer, Christian F. ;

Evans, D. Gareth ;

Lynch, Henry T. ;

Isaacs, Claudine ;

Garber, Judy E. ;

Neuhausen, Susan L. ;

Matloff, Ellen ;

Eeles, Rosalind ;

Pichert, Gabriella ;

Van T'veer, Laura ;

Tung, Nadine ;

Weitzel, Jeffrey N. ;

Couch, Fergus J. ;

Rubinstein, Wendy S. ;

Ganz, Patricia A. ;

Daly, Mary B. ;

Olopade, Olufunmilayo I. ;

Tomlinson, Gail ;

Schildkraut, Joellen ;

Blum, Joanne L. ;

Rebbeck, Timothy R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (09) :967-975

[3] Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers [J].

Graeser, Monika K. ;

Engel, Christoph ;

Rhiem, Kerstin ;

Gadzicki, Dorothea ;

Bick, Ulrich ;

Kast, Karin ;

Froster, Ursula G. ;

Schlehe, Bettina ;

Bechtold, Astrid ;

Arnold, Norbert ;

Preisler-Adams, Sabine ;

Nestle-Kraemling, Carolin ;

Zaino, Mohammad ;

Loeffler, Markus ;

Kiechle, Marion ;

Meindl, Alfons ;

Varga, Dominic ;

Schmutzler, Rita K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5887-5892

[4] Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype [J].

Lakhani, SR ;

Reis-Filho, JS ;

Fulford, L ;

Penault-Llorca, F ;

van der Vjiver, M ;

Parry, S ;

Bishop, T ;

Benitez, J ;

Rivas, C ;

Bignon, YJ ;

Chang-Claude, J ;

Hamann, U ;

Cornelisse, CJ ;

Devilee, P ;

Beckmann, MW ;

Nestle-Krämling, C ;

Daly, PA ;

Haites, N ;

Varley, J ;

Lalloo, F ;

Evans, G ;

Maugard, C ;

Meijers-Heijboer, H ;

Klijn, JGM ;

Olah, E ;

Gusterson, BA ;

Pilotti, S ;

Radice, P ;

Scherneck, S ;

Sobol, H ;

Jacquemier, J ;

Wagner, T ;

Peto, J ;

Stratton, MR ;

McGuffog, L ;

Easton, DF .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5175-5180

[5] Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE [J].

Mavaddat, Nasim ;

Peock, Susan ;

Frost, Debra ;

Ellis, Steve ;

Platte, Radka ;

Fineberg, Elena ;

Evans, D. Gareth ;

Izatt, Louise ;

Eeles, Rosalind A. ;

Adlard, Julian ;

Davidson, Rosemarie ;

Eccles, Diana ;

Cole, Trevor ;

Cook, Jackie ;

Brewer, Carole ;

Tischkowitz, Marc ;

Douglas, Fiona ;

Hodgson, Shirley ;

Walker, Lisa ;

Porteous, Mary E. ;

Morrison, Patrick J. ;

Side, Lucy E. ;

Kennedy, M. John ;

Houghton, Catherine ;

Donaldson, Alan ;

Rogers, Mark T. ;

Dorkins, Huw ;

Miedzybrodzka, Zosia ;

Gregory, Helen ;

Eason, Jacqueline ;

Barwell, Julian ;

McCann, Emma ;

Murray, Alex ;

Antoniou, Antonis C. ;

Easton, Douglas F. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (11) :812-822

[6] Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. [J].

Meijers-Heijboer, H ;

van Geel, B ;

van Putten, WLJ ;

Henzen-Logmans, SC ;

Seynaeve, C ;

Menke-Pluymers, MBE ;

Bartels, CCM ;

Verhoog, LC ;

van den Ouweland, AMW ;

Niermeijer, MF ;

Brekelmans, CTM ;

Klijn, JGM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :159-164

[7] Hereditary Breast and Ovarian Cancer New Genes, New Treatments, New Concepts [J].

Meindl, Alfons ;

Ditsch, Nina ;

Kast, Karin ;

Rhiem, Kerstin ;

Schmutzler, Rita K. .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (19) :323-U13

[8] The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study [J].

Rhiem, Kerstin ;

Engel, Christoph ;

Graeser, Monika ;

Zachariae, Silke ;

Kast, Karin ;

Kiechle, Marion ;

Ditsch, Nina ;

Janni, Wolfgang ;

Mundhenke, Christoph ;

Golatta, Michael ;

Varga, Dominic ;

Preisler-Adams, Sabine ;

Heinrich, Tilman ;

Bick, Ulrich ;

Gadzicki, Dorothea ;

Briest, Susanne ;

Meindl, Alfons ;

Schmutzler, Rita K. .

BREAST CANCER RESEARCH, 2012, 14 (06)

[9] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial [J].

Tutt, Andrew ;

Robson, Mark ;

Garber, Judy E. ;

Domchek, Susan M. ;

Audeh, M. William ;

Weitzel, Jeffrey N. ;

Friedlander, Michael ;

Arun, Banu ;

Loman, Niklas ;

Schmutzler, Rita K. ;

Wardley, Andrew ;

Mitchell, Gillian ;

Earl, Helena ;

Wickens, Mark ;

Carmichael, James .

LANCET, 2010, 376 (9737) :235-244

← 1 →